Navigation Links
Versatile Reporter Vectors for Monitoring Viral Transduction

arker downstream of the b-galactosidase gene in a bicistronic, IRES-containing cassette (Figure 1A).

We first tested the vector by preparing virus (described above) and infecting CHO cells. Transduced cells were fixed and stained in situ with X-gal using the In Situ b-Galactosidase Staining Kit (Stratagene); the resulting transduced cells stained an intense blue (Figure 2). Viral titers were then determined by counting blue-stained cells as a percentage of the total number of cells visible in a microscopic grid. As indicated in Table 1, titers greater than 106 cfu/ml were achieved for CHO cells (the only cell line tested). In a separate experiment, equivalent titers were determined in parallel by both X-gal staining and selection of neomycin-resistant colony formation.2

pFB-Luc Vector

Fig.3

For certain applications in which a rapid and sensitive assessment of gene expression efficiency from the viral promoter in a target cell of choice is required, luciferase is the reporter of choice. In Figure 3, NIH-3T3 cells infected with VSV-G pseudotyped virions made using pFB-Luc at very low MOIs show a dose-responsive luciferase readout. In addition, they display a significant signal above background at an MOI of 1:20,000, which represents an infection of 200,000 cells with approximately 10 virus particles.

Conclusions

Use ViraPort retroviral reporter vectors in conjunction with ViraPort retroviral premade libraries to reveal the efficiency of any retroviral transduction. When carrying out costly and time-consuming gene delivery experiments, where gene products are not readi
'"/>

Source:


Page: All 1 2 3 4 5 6

Related biology technology :

1. A Versatile Power Supply for All Electrophoresis Applications
2. Versatile Vectors for Ponasterone A- Inducible Control of Gene Expression in Mammalian Cells
3. Versatile Transfection Reagent Offers Low Toxicity and Consistent Performance
4. pSilencer 4.1-CMV: Versatile Vectors for Expression of siRNA, miRNA, and mRNA
5. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
6. Stable HeLa Luciferase Reporter Cell Lines Expressing GAL4 Fusion Transactivators
7. New Reporter Plasmids for Studying Interferon-Stimulated Signal Transduction Pathways
8. Genetic Reporter Systems
9. Genetic Reporter Systems
10. Detection of Reporter Gene Activity in Cell Cultures and Murine Epidermis After Helios Gene Gun-Mediated Particle Bombardment
11. A Microtiter-based Assay for the Determination of ID50s of b-lactamase Inhibitors Employing Reporter Substrates Detected at UV or Visible Wavelengths (MaxLine Application Note #20)
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Versatile Reporter Vectors for Monitoring Viral Transduction

(Date:8/27/2008)...in the San Francisco Bay area featured on Hotbed M...ce, the world,s leading,online bioscience job boar... BayBio launched this morning the 2008-2009 Biotec...nce industry in San Francisco and Northern,Califor...h/20080827/CLW095 ), (Logo: http://www.newscom....
(Date:8/27/2008)...., Aug. 27 /- CV Therapeuti... accordance with Nasdaq,marketplace rule 4350, the... non-executive officers due to additional hiring, ... efforts in the United States., The inducement st...mmon,stock and are classified as non-qualified sto...
(Date:8/27/2008)...August 27 /- The Board of,D...Albert Saporta, approved,STALLERGENES, half year c...s) 2007 HY1 2008 HY... % of % of % ...es change, Sales ...
(Date:8/27/2008)...., Aug. 27 /- MedPredict has publishe...ought Leader Insight &,Analysis: Breast Cancer," d...pharma and biotech companies with a stake in the m...se area. MedPredict interviewed renowned North,Ame...o identify the most,promising candidates in clinic...
Breaking Biology Technology:BioSpace and BayBio announce 2008-2009 Biotech Bay(TM) Hotbed Campaign 2CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350 2Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit 2Stallergenes: First Half Year 2008: A 19% Increase in Operating Profit and Net Profit 3Pipeline for Breast Cancer Therapies is Focus of New MedPredict Report 2
...very important to succeed both personally and prof...building alliances with other people in the busine...ps are built, you will be able leverage them to he...make sure you reciprocate and allow your alliances... be mutually beneficial for all parties. Otherwise...
...xperiences were passed down to new businesses at t...e 7 and 8 in Milwaukee at the Hyatt Regency. , ,Ne...ors and professional service providers converged a...k. Seminar members and keynote speakers were chose...ay stronger. , ,Tom Still, president of the Wisco...
...N,s coverage of the Digital Healthcare Conference...ntary reception. Madison, Wis. An executive pan...vendors and decision-makers that agreeing on stand... for performance could create better, or worse, h... Consultants, said that pay-for-performance takes ...
...tudy reported in the June 2005 issue of the Harvar...now predominant. But many companies, even in peopl... processes they need to excel. While organizations...ing capital investments, suppliers and the product...ties in managing people seriously lag. , ,In their...
Other Biology Technology:Don't forget building relationships when building business 2Don't forget building relationships when building business 3Don't forget building relationships when building business 4Conference focuses on experience, challenges of being an entrepreneur 2Conference focuses on experience, challenges of being an entrepreneur 3Conference focuses on experience, challenges of being an entrepreneur 4Experts spar over incentives for health-care providers 2Experts spar over incentives for health-care providers 3Four steps to making talent management a core competence 2Four steps to making talent management a core competence 3Four steps to making talent management a core competence 4
(Date:8/27/2008)... , Juergen Tautz from the University of Wuerzburg...rt of the 2008 EMBO Award for Communication in the...anization (EMBO) awards the prize annually to a pr...nication with the public. The additional award was...ommunication activity on a single organism using a...
(Date:8/26/2008)... , , (Santa Barbara, Calif.) It,s no secret th...les of plants and animals. UC Santa Barbara,s Stev... to test that theory by studying the world,s far-f...onth in the Proceedings of the National Academy o... of extinction rates of species on islands. The pa...
(Date:8/26/2008)... , Today, the European Molecular Biology Organiza... biologist Axel Meyer from the University of Konst... Communication in the Life Sciences. EMBO awards t...ope for outstanding communication with the public....is continuous endeavour to convey complex scientif...
(Date:8/26/2008)... , PORTLAND, Ore. Industry research collaboratio... by Oregon Health & Science University produced in...e OHSU Office of Technology & Research Collaborati...48.6 percent increase over the $6.7 million produc...ncrease over the $2.9 million total five years ago...
Breaking Biology News(10 mins):EMBO recognizes German zoologist for public communication 2Study of islands reveals surprising extinction results 2Study of islands reveals surprising extinction results 3Prominent German biologist wins EMBO Communication Award 2OHSU commercial collaborations have surged 2OHSU commercial collaborations have surged 3Certain vitamin supplements may increase lung cancer risk especially in smokers 13101 1Certain vitamin supplements may increase lung cancer risk especially in smokers 13101 2AstraZeneca Submits sNDA for SEROQUEL XR 28TM 29 for the Treatment of Major Depressive Disorder 3621 1AstraZeneca Submits sNDA for SEROQUEL XR 28TM 29 for the Treatment of Major Depressive Disorder 3621 2AstraZeneca Submits sNDA for SEROQUEL XR 28TM 29 for the Treatment of Major Depressive Disorder 3621 3AstraZeneca Submits sNDA for SEROQUEL XR 28TM 29 for the Treatment of Major Depressive Disorder 3621 4AstraZeneca Submits sNDA for SEROQUEL XR 28TM 29 for the Treatment of Major Depressive Disorder 3621 5AstraZeneca Submits sNDA for SEROQUEL XR 28TM 29 for the Treatment of Major Depressive Disorder 3621 6AstraZeneca Submits sNDA for SEROQUEL XR 28TM 29 for the Treatment of Major Depressive Disorder 3621 7AstraZeneca Submits sNDA for SEROQUEL XR 28TM 29 for the Treatment of Major Depressive Disorder 3621 8Applikon and Finesse Solutions Introduce TruConnect 28TM 29 13099 1Applikon and Finesse Solutions Introduce TruConnect 28TM 29 13099 2Filing of 2007 Annual Report on Form 20 F 3619 1Filing of 2007 Annual Report on Form 20 F 3619 2
...many years, DNA and proteins have been,viewed as t...h RNA seen,as little more than a messenger that sh...s from Whitehead Institute for Biomedical Research...scovered that small,RNA molecules called microRNAs...third of the genome,s protein-coding regions. In o...
...archers at the University of Minnesota have identi...l purpura fulminans. The disease begins as a respi...Staphylococcus aureus. The infection then moves to... that activate large numbers of T cells), often le...ura fulminans has been identified in five cases in...
...ntists at Wake Forest University Baptist Medical C... to find what activates the spores in anthrax, the...ws. , "A key aspect of anthrax spore biology conce...ant spore becomes a reproductive, disease-causing ...ncipal investigator. "The potential importance of ...
...oved Outcomes Software (IOS) today,announced the r...w,versions of the award-winning Gene Expression an...releases are focused primarily on importing and an...r many of our customers. For,example, we have inte...st versions of the products (previously the Protei...
Other Biology News:Study finds more than one-third of human genome regulated by RNA 2U of M researcher examines newly emerging deadly disease 2Scientists seek answers on what activates deadly anthrax spores 2Improved Outcomes Releases GeneLinker(TM) Gold and Platinum Version 4.6 2Improved Outcomes Releases GeneLinker(TM) Gold and Platinum Version 4.6 3